PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma

Gynecologic Oncology

Volumn 132, Issue 1, 2014, Pages 188-193

  McIntyre, John B ^a,c   Nelson, Gregg S ^a,c   Ghatage, Prafull ^a,c   Morris, Don ^a,c   Duggan, Máire A ^a,d   Lee, Cheng Han ^b   Doll, Corinne M ^a,c   Köbel, Martin ^a,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d CALGARY LABORATORY SERVICES   (Canada)

Author keywords

Endometrial cancer PIK3CA missense mutation; Endometrioid carcinoma; Prognosis

Indexed keywords

DNA; MISMATCH REPAIR PROTEIN; PIK3CA PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; DISEASE SPECIFIC SURVIVAL; DNA SEQUENCE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EXON; FEMALE; GENE LOSS; GENETIC ANALYZER; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MIDDLE AGED; MISSENSE MUTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; VERY ELDERLY;

ENDOMETRIAL CANCER PIK3CA MISSENSE MUTATION; ENDOMETRIOID CARCINOMA; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DNA MISMATCH REPAIR; ENDOMETRIAL NEOPLASMS; EXONS; FEMALE; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM GRADING; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84892808126     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.11.015     Document Type: Article

References (40)

1. C.B. Gilks, E. Oliva, and R.A. Soslow Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma Am J Surg Pathol 37 6 2013 874 881
2. E.G. Silva, M.T. Deavers, D.C. Bodurka, and A. Malpica Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol:Off J Soc Gynecol Pathol 25 1 2006 52 58
3. G. Han, D. Sidhu, M.A. Duggan, J. Arseneau, M. Cesari, and P.B. Clement et al. Reproducibility of histological cell type in high-grade endometrial carcinoma Mod Pathol 2013 10.1038/modpathol.2013.102
4. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 9484 2005 491 505
5. L.N. Hoang, M.K. McConechy, M. Kobel, G. Han, M. Rouzbahman, and B. Davidson et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas Am J Surg Pathol 37 9 2013 1421 1432
6. M.K. McConechy, J. Ding, M.C. Cheang, K.C. Wiegand, J. Senz, and A.A. Tone et al. Use of mutation profiles to refine the classification of endometrial carcinomas J Pathol 228 1 2012 20 30
7. N. Cancer Genome Atlas Research, C. Kandoth, N. Schultz, A.D. Cherniack, R. Akbani, and Y. Liu et al. Integrated genomic characterization of endometrial carcinoma Nature 497 7447 2013 67 73
8. M. Le Gallo, A.J. O'Hara, M.L. Rudd, M.E. Urick, N.F. Hansen, and N.J. O'Neil et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes Nat Genet 44 12 2012 1310 1315
9. E. Kuhn, R.C. Wu, B. Guan, G. Wu, J. Zhang, and Y. Wang et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses J Natl Cancer Inst 104 19 2012 1503 1513
10. S. Zhao, M. Choi, J.D. Overton, S. Bellone, D.M. Roque, and E. Cocco et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma Proc Natl Acad Sci U S A 110 8 2013 2916 2921
11. G.L. Mutter, M.C. Lin, J.T. Fitzgerald, J.B. Kum, J.P. Baak, and J.A. Lees et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers J Natl Cancer Inst 92 11 2000 924 930
12. B. Guan, T.L. Mao, P.K. Panuganti, E. Kuhn, R.J. Kurman, and D. Maeda et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma Am J Surg Pathol 35 5 2011 625 632
13. H. Tashiro, C. Isacson, R. Levine, R.J. Kurman, K.R. Cho, and L. Hedrick p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis Am J Pathol 150 1 1997 177 185
14. T. Okuda, A. Sekizawa, Y. Purwosunu, M. Nagatsuka, M. Morioka, and M. Hayashi et al. Genetics of endometrial cancers Obstet Gynecol Int 2010 2010 984013
15. M.K. McConechy, M.S. Anglesio, S.E. Kalloger, W. Yang, J. Senz, and C. Chow et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas J Pathol 223 5 2011 567 573
16. L. Catasus, A. Gallardo, M. Cuatrecasas, and J. Prat Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis Mod Pathol 22 4 2009 522 529
17. D.A. Garcia-Dios, D. Lambrechts, L. Coenegrachts, I. Vandenput, A. Capoen, and P.M. Webb et al. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma Gynecol Oncol 128 2 2013 327 334
18. Y. Dong, X. Yang, O. Wong, X. Zhang, Y. Liang, and Y. Zhang et al. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3′-kinase pathway alterations might be associated with favorable prognosis Hum Pathol 43 8 2012 1197 1205
19. W. Sieh, M. Kobel, T.A. Longacre, D.D. Bowtell, A. Defazio, and M.T. Goodman et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study Lancet Oncol 14 9 2013 853 862
20. M. Kobel, A. Reuss, A. Bois, S. Kommoss, F. Kommoss, and D. Gao et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas J Pathol 222 2 2010 191 198
21. G.S. Nelson, A. Pink, S. Lee, G. Han, D. Morris, and T. Ogilvie et al. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome Gynecol Oncol 131 2 2013 309 314
22. J.B. McIntyre, J.S. Wu, P.S. Craighead, T. Phan, M. Kobel, and S.P. Lees-Miller et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy Gynecol Oncol 128 3 2013 409 414
23. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, and S. Szabo et al. High frequency of mutations of the PIK3CA gene in human cancers Science 304 5670 2004 554
24. K. Oda, D. Stokoe, Y. Taketani, and F. McCormick High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma Cancer Res 65 23 2005 10669 10673
25. D. Koul, J. Fu, R. Shen, T.A. LaFortune, S. Wang, and N. Tiao et al. Antitumor activity of NVP-BKM120 - a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells Clin Cancer Res 18 1 2012 184 195
26. A. Herzog, Y. Bian, R. Vander Broek, B. Hall, J. Coupar, and H. Cheng et al. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer Clin Cancer Res 19 14 2013 3808 3819
27. J. Abubaker, P. Bavi, S. Al-Harbi, M. Ibrahim, A.K. Siraj, and N. Al-Sanea et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population Oncogene 27 25 2008 3539 3545
28. F.L. Day, R.N. Jorissen, L. Lipton, D. Mouradov, A. Sakthianandeswaren, and M. Christie et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer Clin Cancer Res 19 12 2013 3285 3296
29. B.A. Clarke, and K. Cooper Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas Adv Anat Pathol 19 4 2012 231 238
30. H.B. Salvesen, S.L. Carter, M. Mannelqvist, A. Dutt, G. Getz, and I.M. Stefansson et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation Proc Natl Acad Sci U S A 106 12 2009 4834 4839
31. M.E. Urick, M.L. Rudd, A.K. Godwin, D. Sgroi, M. Merino, and D.W. Bell PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer Cancer Res 71 12 2011 4061 4067
32. B. Weigelt, P.H. Warne, M.B. Lambros, J.S. Reis-Filho, and J. Downward PI3K pathway dependencies in endometrioid endometrial cancer cell lines Clin Cancer Res 19 13 2013 3533 3544
33. A.G. Dumont, S.N. Dumont, and J.C. Trent The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer Chin J Cancer 31 7 2012 327 334
34. X. Liao, T. Morikawa, P. Lochhead, Y. Imamura, A. Kuchiba, and M. Yamauchi et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review Clin Cancer Res 18 8 2012 2257 2268
35. L. Zhang, L. Shi, X. Zhao, Y. Wang, and W. Yue PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma Oncol Targets Ther 6 2013 497 502
36. M.L. Rudd, J.C. Price, S. Fogoros, A.K. Godwin, D.C. Sgroi, and M.J. Merino et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas Clin Cancer Res 17 6 2011 1331 1340
37. S.B. Korets, S. Czok, S.V. Blank, J.P. Curtin, and R.J. Schneider Targeting the mTOR/4E-BP pathway in endometrial cancer Clin Cancer Res 17 24 2011 7518 7528
38. F. Janku, J.J. Wheler, S.N. Westin, S.L. Moulder, A. Naing, and A.M. Tsimberidou et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations J Clin Oncol 30 8 2012 777 782
39. F. Janku, J.J. Wheler, A. Naing, G.S. Falchook, D.S. Hong, and V.M. Stepanek et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials Cancer Res 73 1 2013 276 284
40. X. Liao, P. Lochhead, R. Nishihara, T. Morikawa, A. Kuchiba, and M. Yamauchi et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival N Engl J Med 367 17 2012 1596 1606